The Indian Times
–
The Drugs Controller General of India (DCGI) approved 2-deoxy-D-glucose (2-DG) as an oral drug against the coronavirus.
–
GridHEALTH.id – As all countries fight the second wave of infections corona virus the vicious, The Drugs Controller General of India (DCGI) approved 2-deoxy-D-glucose (2-DG) developed by the Defense Research and Development Organization (DRDO) for the treatment of corona virus.
Oral medicine against Covid-19 it has been shown to be effective against multiplication SARS-CoV-2 and works against all variants Covid-19.
According to the researchers, research shows that 2-DG effectively inhibits doubling SARS-CoV-2 and can be used as a treatment regimen.
How Glycolytic inhibitor 2-DG works by weakening doubling SARS-CoV-2 in the host cell and attenuates the infective potential of the progeny virion (virus).
Thus the conclusion of a study by a combination of researchers from Center for Cellular and Molecular Biology (CCMB), Hyderabad, Institute of Nuclear Medicine di New Delhi, dan Academy for Scientific and Innovative Research by Ghaziabad.
“Although the effect of 2-DG has been analyzed in only 2 variants SARS-CoV-2 (B.6 and B.1.1.7), its anti-virus properties are suggested to be universal on all variants SARS-CoV-2. CoV-2, because 2-DG interferes with the metabolic needs of virus-infected host cells,” says the research study published on the preprinted online server ‘BioRxiv’.
Also Read: Turkish Scientists Prove Ribavirin Effective in Covid-19 Treatment
Also Read: 3 Tips on How to Inject Insulin Correctly for People with Diabetes
These findings highlight infection SARS-CoV-2 which mediates an increase in glucose metabolism in host cells, which can be targeted for therapeutic applications.
PROMOTED CONTENT
Featured Videos
– .
